Hisamitsu Pharmaceutical Co., Inc.

As of August 31, 2024, Hisamitsu Pharmaceutical Co., Inc. has 73.34M shares outstanding.

As of August 31, 2024, Hisamitsu Pharmaceutical Co., Inc. trades at a trailing price-to-earnings ratio of 20.76. The price-to-sales ratio is 2.02, and the price-to-book ratio stands at 1.18.

As of August 31, 2024, Hisamitsu Pharmaceutical Co., Inc. trades at an EV/EBITDA multiple of 13.42 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.23 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 13.42 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Hisamitsu Pharmaceutical Co., Inc. trades at an EV/FCF ratio of 9,323.65, comparing the total takeover cost of the business to the cash it actually generates for all capital providers.

As of August 31, 2024, Hisamitsu Pharmaceutical Co., Inc. maintains a current ratio of 3.53, meaning it holds 3.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.40, indicating conservative leverage, while an interest coverage ratio of 510.26 demonstrates strong ability to service its debt obligations.

Over the twelve months ended August 31, 2024, Hisamitsu Pharmaceutical Co., Inc. posted a return on equity (ROE) of 5.79, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 3.61 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 4.22, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 5.52, useful for judging operating efficiency across full business cycles. Inventory turnover of 3.01 indicates how many times Hisamitsu Pharmaceutical Co., Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

These figures cover the twelve months ended August 31, 2024. That works out to an effective tax rate of 26.57, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items.

As of the close on May 11, 2026, Hisamitsu Pharmaceutical Co., Inc.'s stock has gained approximately 38.37% over the past 52 weeks. The 50-day moving average sits at 6,040.02, while the 200-day moving average is 4,983.58.

Over the twelve months ended August 31, 2024, Hisamitsu Pharmaceutical Co., Inc. posted a gross margin of 56.42, reflecting its pricing power and cost economics. The operating margin of 9.17 and net profit margin of 9.75 provide insight into operational efficiency.

As of August 31, 2024, Hisamitsu Pharmaceutical Co., Inc. has an Altman Z-Score of 4.55, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.